Both 340B stakeholders endorsed an independent data clearinghouse and statutory patient definition amid program growth ...
Rotterdam-based diagnosis (2 of oligo/anovulation, hyperandrogenism, polycystic ovarian morphology) persists, but ...
A finalized mandatory model will test whether tying Medicare Part B drug rebates to international prices can lower costs for ...
Lung cancer screening eligibility increased markedly from 2018–2023 under USPSTF criteria, reflecting aging and substantial ...
Diagnosed atopic dermatitis (AD) affected about 6.9 million insured people in the US in 2023, but roughly half of them filled ...
LIBERTY met all primary/secondary endpoints, with lower 6-day TEAEs/ISRs/hypersensitivity (56.5% vs 91.4%) and systemic AEs ...
In "Closing Reflections on the Future of Vitiligo Care," each panelist shares closing reflections on where vitiligo care is ...
Sean Wharton, MD, PharmD, discusses new data on survodutide from the phase 3 SYNCHRONIZE-2 trial. Survodutide (Boehringer Ingelheim), a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor ...
Weekly survodutide 3.6 mg/6.0 mg achieved up to 13.1% mean weight loss at week 76 versus 3.1% with placebo, meeting ...
FDA expanded mavacamten’s indication to include pediatric patients ≥66 lb with symptomatic oHCM, positioning it as the only FDA-approved oHCM therapy for children and adolescents. SCOUT-HCM randomized ...
Dr. Chung asks what operational changes practices should prioritize to prepare for an expanding hepatitis B treatment ...
AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results